Medicare Enrolled
Dr. Shaina Rozell, MD
Medical Oncology · Chicago Ridge, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rozell from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rozell?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rozell
Dr. Shaina Rozell is a medical oncology specialist in Chicago Ridge, IL, with 16 years of NPI registration. Based on federal Medicare data, Dr. Rozell performed 16,182 Medicare services across 667 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rozell received a total of $272,552 from 81 pharmaceutical and/or device companies across 1101 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rozell is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 18% volume in IL
$272,552 industry payments
Medicare Practice Summary
Medicare Utilization ↗16,182
Medicare services
Top 18% in IL for medical oncology
667
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,011 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
12,150 | $0 | $7 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,150 | $1 | $122 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,108 | $0 | $2 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
423 | $98 | $400 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
287 | $65 | $270 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
193 | $24 | $152 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
190 | $13 | $105 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
166 | $107 | $686 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
92 | $53 | $334 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
81 | $59 | $270 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
75 | $23 | $156 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
59 | $140 | $750 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
50 | $1,281 | $4,120 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 48 | $401 | $638 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
36 | $11 | $93 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $125 | $620 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
29 | $1 | $7 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
16 | $8 | $19 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.8% high complexity
91.4% medium
5.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$272,552
Total received (2018-2024)
Avg $38,936/year across 7 years
Top 4% in IL for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
81
Companies
1,101
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$239,750 (88.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$19,003 (7.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,488 (4.6%)
Other
Charitable contributions, space rental, and other categories
$1,312 (0.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$148,228
2023
$99,286
2022
$17,836
2021
$1,680
2020
$978
2019
$2,428
2018
$2,115
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Gilead Sciences, Inc.
$86,846
AstraZeneca Pharmaceuticals LP
$38,004
Daiichi Sankyo Inc.
$16,719
PFIZER INC.
$1,996
Novartis Pharmaceuticals Corporation
$1,312
Regeneron Healthcare Solutions, Inc.
$1,301
Janssen Biotech, Inc.
$252
Merck Sharp & Dohme LLC
$195
E.R. Squibb & Sons, L.L.C.
$167
Incyte Corporation
$137
Astellas Pharma US Inc
$118
Tempus AI, Inc
$116
ABBVIE INC.
$98
Pharmacosmos Therapeutics Inc.
$86
GlaxoSmithKline, LLC.
$84
Genentech USA, Inc.
$81
TerSera Therapeutics LLC
$64
Lilly USA, LLC
$62
Alexion Pharmaceuticals, Inc.
$56
GENZYME CORPORATION
$48
SOBI, INC
$45
SERVIER PHARMACEUTICALS LLC
$40
Ipsen Biopharmaceuticals, Inc
$36
Kite Pharma, Inc.
$34
Takeda Pharmaceuticals U.S.A., Inc.
$32
JAZZ PHARMACEUTICALS INC.
$29
SpringWorks Therapeutics, Inc.
$28
EMD Serono, Inc.
$27
Amneal Pharmaceuticals LLC
$26
Sumitomo Pharma America, Inc.
$25
ImmunoGen, Inc.
$22
Mirati Therapeutics, Inc.
$21
GE HEALTHCARE
$21
PUMA BIOTECHNOLOGY, INC.
$20
Eisai Inc.
$19
Rigel Pharmaceuticals, Inc.
$19
Agios Pharmaceuticals, Inc.
$15
Celgene Corporation
$14
Bayer Healthcare Pharmaceuticals Inc.
$13
Top 3 companies account for 95.5% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$143,801
AstraZeneca Pharmaceuticals LP
$73,759
Daiichi Sankyo Inc.
$32,073
Regeneron Healthcare Solutions, Inc.
$2,952
PFIZER INC.
$2,771
Novartis Pharmaceuticals Corporation
$2,347
GlaxoSmithKline, LLC.
$1,972
NOVARTIS PHARMACEUTICALS CORPORATION
$1,914
Merck Sharp & Dohme Corporation
$984
E.R. Squibb & Sons, L.L.C.
$932
Janssen Biotech, Inc.
$778
Incyte Corporation
$747
Amgen Inc.
$674
Lilly USA, LLC
$597
Genentech USA, Inc.
$545
Seagen Inc.
$482
Merck Sharp & Dohme LLC
$420
Celgene Corporation
$276
Pharmacyclics LLC, An AbbVie Company
$244
Exelixis Inc.
$240
Astellas Pharma US Inc
$203
Alexion Pharmaceuticals, Inc.
$186
GENZYME CORPORATION
$165
EMD Serono, Inc.
$150
TerSera Therapeutics LLC
$148
Rigel Pharmaceuticals, Inc.
$136
Global Blood Therapeutics, Inc.
$131
TESARO, Inc.
$124
JAZZ PHARMACEUTICALS INC.
$117
Tempus AI, Inc
$116
ABBVIE INC.
$113
Ipsen Biopharmaceuticals, Inc
$113
Myriad Genetic Laboratories, Inc.
$105
Pharmacosmos Therapeutics Inc.
$104
Takeda Pharmaceuticals U.S.A., Inc.
$101
SANOFI-AVENTIS U.S. LLC
$99
Bayer HealthCare Pharmaceuticals Inc.
$95
Puma Biotechnology, Inc.
$95
Eisai Inc.
$91
G1 Therapeutics, Inc.
$90
AMAG Pharmaceuticals, Inc.
$85
Novo Nordisk Inc
$83
Kite Pharma, Inc.
$72
AbbVie, Inc.
$69
MorphoSys, US Inc.
$65
BeiGene USA, Inc.
$64
Taiho Oncology, Inc.
$58
EISAI INC.
$56
Mirati Therapeutics, Inc.
$55
Pharmacyclics LLC, an AbbVie Company
$54
Janssen Pharmaceuticals, Inc
$54
ImmunoGen, Inc.
$53
Deciphera Pharmaceuticals Inc.
$47
Dova Pharmaceuticals
$47
SOBI, INC
$45
Sumitomo Pharma America, Inc.
$45
PUMA BIOTECHNOLOGY, INC.
$44
SERVIER PHARMACEUTICALS LLC
$40
Boehringer Ingelheim Pharmaceuticals, Inc.
$39
GE HEALTHCARE
$37
Coherus Biosciences Inc.
$34
Tactile Systems Technology Inc
$33
Clovis Oncology, Inc.
$31
SpringWorks Therapeutics, Inc.
$28
Amneal Pharmaceuticals LLC
$26
CTI BioPharma Corp.
$25
Jazz Pharmaceuticals Inc.
$24
Genmab U.S., Inc.
$24
Blueprint Medicines Corporation
$23
Advanced Accelerator Applications
$22
Sobi, Inc
$22
Karyopharm Therapeutics Inc.
$20
Seattle Genetics, Inc.
$19
Agios Pharmaceuticals, Inc.
$15
AVEO Pharmaceuticals, Inc.
$15
Myovant Sciences Inc.
$15
Kyowa Kirin, Inc.
$14
TOLMAR Pharmaceuticals, Inc.
$14
Bayer Healthcare Pharmaceuticals Inc.
$13
Medtronic USA, Inc.
$13
AbbVie Inc.
$13
Top 3 companies account for 91.6% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · ANDEXXA · AVASTIN · AYVAKIT · Abraxane · Alecensa · Avastin · BAVENCIO · BLENREP · BOSULIF · BRUKINSA · Balversa · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · EMEND · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Elahere · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FLEXITOUCH · FOTIVDA · Fabhalta · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Novoeight · Nplate · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OSTEOCOOL RF ABLATION · OXBRYTA · Onivyde · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PREZCOBIX · PROMACTA · Padcev · Perjeta · Pomalyst · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SUTENT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEPMETKO · TIVDAK · TUKYSA · Tavalisse · Tazverik · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xofigo · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (88%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for medical oncology in IL.
Geographic Context
Medical oncologists within 10 mi
77
Per 100K population
1.5
County median income
$81,797
Nearest hospital
ADVOCATE CHRIST HOSPITAL & MEDICAL CENTER
1.6 mi
1.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rozell is a mixed practice specialist, with above-average Medicare volume (top 18% in IL), with speaking/promotional industry engagement in the top 4% of IL peers, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rozell experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Rozell performed 12,150 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rozell receive payments from pharmaceutical companies?
Yes. Dr. Rozell received a total of $272,552 from 81 companies across 1,101 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rozell's costs compare to other medical oncologists in Chicago Ridge?
Dr. Rozell's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rozell) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Chicago Ridge
Browse medical oncologists in Chicago Ridge ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in IL
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in IL
Which IL medical oncologists receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology